Neuronetics, Inc. (STIM) recently announced that additional payors have updated the coverage of TMS (transcranial magnetic stimulation). This upgrade is aimed at reducing the access barriers for patients with major depressive disorder (MDD). This expanded access will help people receive treatments, such as the company's NeuroStar TMS therapy, earlier in their treatment regimen. STIM Stock Likely Trend Following the News Following the news, STIM stock fell 1.8% to 93 cents on Friday. However, the company is ...